Moorthy Vasee S, Good Michael F, Hill Adrian V S
MRC Laboratories, Banjul, The Gambia.
Lancet. 2004 Jan 10;363(9403):150-6. doi: 10.1016/S0140-6736(03)15267-1.
Large gains in the reduction of malaria mortality in the early 20th century were lost in subsequent decades. Malaria now kills 2-3 million people yearly. Implementation of malaria control technologies such as insecticide-treated bednets and chemotherapy could reduce mortality substantially, but an effective malaria vaccine is also needed. Advances in vaccine technology and immunology are being used to develop malaria subunit vaccines. Novel approaches that might yield effective vaccines for other diseases are being evaluated first in malaria. We describe progress in malaria vaccine development in the past 5 years: reasons for cautious optimism, the type of vaccine that might realistically be expected, and how the process could be hastened. Although exact predictions are not possible, if sufficient funding were mobilised, a deployable, effective malaria vaccine is a realistic medium-term to long-term goal.
20世纪初在降低疟疾死亡率方面取得的巨大成果在随后几十年中付诸东流。如今，疟疾每年导致200万至300万人死亡。实施诸如经杀虫剂处理的蚊帐和化疗等疟疾控制技术可大幅降低死亡率，但仍需要一种有效的疟疾疫苗。疫苗技术和免疫学的进展正被用于研发疟疾亚单位疫苗。可能为其他疾病带来有效疫苗的新方法首先在疟疾研究中进行评估。我们描述了过去5年疟疾疫苗研发的进展：谨慎乐观的原因、有望实际推出的疫苗类型以及如何加快这一进程。尽管无法做出确切预测，但如果能筹集到足够资金，一种可部署、有效的疟疾疫苗是现实的中长期目标。
